JAZZ Jazz Pharmaceuticals plc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1232524 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.5%
TTM net income YoY155.9%
TTM EPS YoY154.9%
Revenue 3-yr CAGR7.5%
Net income 3-yr CAGR37.1%
Margins
Gross margin—
Operating margin9.0%
Net margin4.4%
FCF margin34.4%
EBITDA margin9.8%
Returns
ROE5.1%
ROA1.8%
ROIC (approx.)4.3%
Asset turnover0.40x
Leverage & solvency
Liabilities / assets65.1%
Debt / equity1.33x
Current ratio1.82x
Interest coverage—
Cash quality & payout
Operating cash flow / net income8.22x
Accruals ratio-12.7%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B |
| R&D expense | $782.74M | $884.00M | $849.66M | $590.45M | $505.75M |
| SG&A expense | $1.81B | $1.39B | $1.34B | $1.42B | $1.45B |
| Operating income | -$430.24M | $716.63M | $578.58M | -$65.53M | $170.28M |
| Interest expense | — | — | $32.80M | $32.80M | $89.90M |
| Pretax income | -$627.86M | $470.35M | $297.93M | -$372.78M | -$112.84M |
| Income tax | -$272.44M | -$91.43M | -$119.91M | -$158.65M | $216.12M |
| Net income | -$356.15M | $560.12M | $414.83M | -$224.06M | -$329.67M |
| EBITDA | -$388.64M | $749.43M | $608.98M | -$35.23M | $196.98M |
| EPS (basic) | -5.84 | 9.06 | 6.55 | -3.58 | -5.52 |
| EPS (diluted) | -5.84 | 8.65 | 6.10 | -3.58 | -5.52 |
| Weighted avg. shares (diluted) | 60.98M | 66.01M | 72.07M | 62.54M | 59.69M |
| Balance sheet | |||||
| Cash & equivalents | $1.39B | $2.41B | $1.51B | $881.48M | $591.45M |
| Receivables | $830.70M | $716.76M | $705.79M | $651.49M | $563.36M |
| Inventory | $417.00M | $480.44M | $597.04M | $714.06M | $1.07B |
| Current assets | $4.17B | $4.63B | $3.44B | $2.61B | $2.61B |
| PP&E, net | $199.90M | $173.41M | $169.65M | $228.05M | $256.84M |
| Goodwill | $1.83B | $1.72B | $1.75B | $1.69B | $1.83B |
| Intangibles | $4.43B | $4.76B | $5.42B | $5.79B | $7.15B |
| Total assets | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B |
| Current liabilities | $2.24B | $1.04B | $1.54B | $933.19M | $809.30M |
| Short-term debt | $1.03B | $31.00M | $604.95M | $31.00M | $31.00M |
| Long-term debt | $4.33B | $6.08B | $5.11B | $5.69B | $6.02B |
| Total debt | $5.36B | $6.11B | $5.71B | $5.72B | $6.05B |
| Total liabilities | $7.34B | $7.92B | $7.66B | $7.75B | $8.33B |
| Shareholders' equity | $4.32B | $4.09B | $3.74B | $3.09B | $3.97B |
| Net debt | $3.97B | $3.70B | $4.21B | $4.84B | $5.46B |
| Shares outstanding | 61.44M | 60.63M | 62.26M | 63.21M | 61.63M |
| Cash flow statement | |||||
| Operating cash flow | $1.36B | $1.40B | $1.09B | $1.27B | $778.51M |
| Capital expenditure | $58.75M | $38.07M | $23.96M | $29.05M | $27.64M |
| Free cash flow | $1.30B | $1.36B | $1.07B | $1.24B | $750.87M |
| Investing cash flow | -$1.51B | -$508.19M | -$163.06M | -$446.23M | -$5.21B |
| Financing cash flow | -$873.38M | $20.52M | -$305.25M | -$529.49M | $3.97B |
| Depreciation & amortization | $41.60M | $32.80M | $30.40M | $30.30M | $26.70M |
| Stock-based compensation | $291.13M | $248.04M | $226.84M | $222.00M | $189.01M |
| Share buybacks | $125.02M | $311.43M | $269.76M | $54,000 | $0 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.